Comprehensive capabilities. Breakthrough performance.
|Current||Single-phase circuit 15 A|
|Temperature||18°C – 27°C / 64.4°F – 80.6°F|
|Humidity||20% to 80%|
|Altitude||Up to 2,000 m (6,562 ft)|
|Noise metrics||< 67 dB|
|Specimen collection type||BD SurePath™ Liquid-based Pap Test Vials|
BD Molecular Aliquot Tubes
BD Onclarity™ HPV Liquid-based Cytology (LBC) Specimen
ThinPrep® PreservCyt® Solution
|Reagent/consumable capacity||BD COR™ GX Instrument: 180 HPV tests; 1,056 tips (11 tip trays)|
BD COR™ PX Instrument: 35 racks; 192 tips (2 trays; buffer)
|Waste capacity||Solid: 960 conversions (24 hours)|
Liquid: 2,160 tests (3 days)
*Capacity and throughput may vary based on specimen types.
The BD COR™ System automates the BD women’s health assays that were designed to address real clinical unmet needs. The range of Women’s Health assays has been designed over years, with robust research and development efforts and with demonstrated clinical precision. Learn more about BD Women’s Health Assays on BD Women's Health
The BD Onclarity™ HPV Assay is the only FDA-approved assay with extended genotyping out of either the BD SurePath™ Liquid-based Pap Test or the Hologic ThinPrep® Pap Test, positioning your laboratory at the forefront of cervical cancer screening, by enabling you to provide more actionable information to clinicians.
The BD CTGCTV2 assay performed on the BD COR™ System is designed to be used with the BD Molecular specimen collection and transport devices for male and female urine, vaginal, endocervical swabs, and liquid based cytology specimens (Thinprep® PreservCyt Solution). The assay is also indicated for use with asymptomatic and symptomatic individuals to aid in the diagnosis of chlamydial urogenital disease, gonococcal urogenital disease and/or trichomoniasis.